How to judge whether the treatment effect of Larotrectinib is showing

Larotrectinib is a highly selective TRK inhibitor, mainly used to treat patients with solid tumors carrying NTRK gene fusions. To determine whether the treatment effect is evident, a comprehensive judgment is usually made based on multiple factors such as imaging examinations, changes in tumor markers, improvement in clinical symptoms, and doctor evaluation standards.

First of all, imaging examination is the most direct way to evaluate the efficacy of larotrectinib. Regular scans of the tumor are performed before and after treatment through CT or MRI. Doctors will judge whether the tumor volume has shrunk based on the RECIST standards (Effectiveness Evaluation Standards for Solid Tumors). If significant tumor shrinkage occurs 4-8 weeks after treatment, or partial remission (PR) or even complete remission (CR) occurs, it means that the drug has begun to work.

Secondly, the improvement of patients’ subjective symptoms can also help judge the efficacy. For example, pain relief, dyspnea relief, appetite and physical strength recovery, etc. may be symptoms of disease remission. This type of improvement usually gradually appears 2-4 weeks after taking the drug, and has a significant impact on the quality of life of advanced patients in particular. It needs to be evaluated based on daily observation and self-reporting of patients.

Thirdly, dynamic changes in tumor markers are also reference indicators for judging therapeutic efficacy. Some patients will be accompanied by an increase in specific tumor markers (such as CEA, CA125, etc.). If these indicators show a downward trend after taking the drug, it may also indicate that the drug is working. However, such indicators are not applicable to all patients and are more used as auxiliary judgment tools.

Finally, the doctor will make a comprehensive judgment based on the overall evaluation and laboratory tests during the treatment course to determine whether the treatment expectations are met. If there are no imaging changes, symptoms do not improve, or the condition worsens after taking the medication for a period of time (usually 6-8 weeks), it may be necessary to evaluate whether there is drug resistance or drug absorption problems, or to change the treatment plan. Therefore, regular follow-up visits and multidisciplinary evaluation are crucial to determine the efficacy of larotrectinib.

Reference materials:https://www.drugs.com/